SPIRITT Research Becomes Latest CRO to Join MedNet Solutions' iMedNet Partner Program
SPIRITT Selects iMedNet EDC for its eClinical Flexibility and Ease of Use
MedNet Solutions, a global life sciences technology company specializing in clinical study management systems, is pleased to announce that SPIRITT Research, a boutique research services organization with a passion for improving patient treatment outcomes and quality of life, has joined MedNet’s iMedNet Partner Program. SPIRITT will leverage iMedNet EDC, MedNet’s flagship eClinical solution, to get their research studies set up quickly, easily and cost-effectively.
“SPIRITT is an ideal partner for MedNet, given our companies’ deep, shared expertise supporting orthopedic and spine related research, as well as post market studies and registries,” remarked John M. (Rob) Robertson, President and CEO of MedNet Solutions. “We’re confident that our organizations will work very well together and that iMedNet EDC will provide SPIRITT with the technology infrastructure they need to facilitate effective and efficient research.”
“We are very pleased to be partnering with MedNet Solutions,” commented Francine Schranck, President of SPIRITT. “The iMedNet product is one of the best clinical trial management systems we’ve seen, and we recommend it without reservation.”
Matthew Britt, Director of Clinical Affairs at SPIRITT, added, “We are asked all the time by our clients about the best solutions to support them in their various clinical trials, and because of its flexibility and ease of use, iMedNet is a logical choice.”
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
Managing Side Effects and Dosing in Off-Label GLP-1 Use with Help from Real-World Evidence
July 18th 2025Shipra Patel, global therapeutic area section head, endocrinology, global head, pediatrics, Parexel, explains how real-world data is helping researchers navigate gastrointestinal side effects, dose flexibility, and long-term tolerability in off-label GLP-1 use.
Anselamimab Misses Primary Endpoint in Phase III CARES Trials for AL Amyloidosis
July 17th 2025In the Phase III CARES trials, anselamimab did not meet the primary endpoint for advanced-stage AL amyloidosis, but a prespecified subgroup analysis revealed meaningful improvements in survival and cardiovascular outcomes.
